A PCR-Based Approach to Hammerhead Ribozyme Synthesis

  • Katalin Karikó
  • Elliot S. Barnathan
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 11)


Inactivation of gene expression by antisense mechanisms in general and by ribozymes in particular show great promise as a research tool as well as therapeutic agent in selectively reducing mRNA species and thus decreasing subsequent protein synthesis (for reviews see refs. 1 and 2).


Polymerase Chain Reaction Hammerhead Ribozyme Acrylamide Concentrate Lower Primer Ethidium Bromide Solution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Marschall, P., Thomson, J B., and Eckstein, F (1994) Inhibition of gene expression with ribozymes. Cell. Mol NeuroBiol 14, 523–538.PubMedCrossRefGoogle Scholar
  2. 2.
    Rossi, J. J. (1995) Controlled, targeted, intracellular expression of ribozymes progress and problems. TIBTECH 13, 301–306Google Scholar
  3. 3.
    Cameron, F H. and Jennings, P. A. (1989) Specific gene suppression by engineered ribozymes in monkey cells. Proc Natl. Acad Sci USA 86, 9139–9143PubMedCrossRefGoogle Scholar
  4. 4.
    Sarver, N, Cantin, E. M., Chang, P S., Zaia, J. A., Ladne, P A, Stephens, D A, and Rossi, J J. (1990) Ribozymes as potential anti-HIV-1 therapeutic agents Science 247, 1222–1225.PubMedCrossRefGoogle Scholar
  5. 5.
    Ohta, Y., Kijima, H., Ohkawa, T., Kashini-Sabeth, M., and Scanlon, K J (1996) Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells. Nucleic Acids Res 24, 938–942.PubMedCrossRefGoogle Scholar
  6. 6.
    Sioud, M., Natvig, J. B., and Forre, O (1992) Preformed ribozyme destroys tumour necrosis factor mRNA in human cells J, Mol Biol 223, 831–835.CrossRefGoogle Scholar
  7. 7.
    Kiehntopf, M, Brach, M A, Licht, T, Petschauer, S, Karawajew, L, Kirschning, C, and Herrmann, F. (1994) Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J 13, 4645–4652.PubMedGoogle Scholar
  8. 8.
    Leopold, L H., Shore, S K, Newkirk, T 0, Reddy, R M. V, and Reddy, E. P. (1995) Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood 85, 2162–2170.PubMedGoogle Scholar
  9. 9.
    Pieken, W A., Olsen, D B, Benseler, F, Aurup, H., and Eckstein, F. (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253, 314–317.PubMedCrossRefGoogle Scholar
  10. 10.
    Hoffman, L M and Johnson, M G (1994) Enzymatic synthesis of milligram quantities of ribozymes in small volumes. BioTechniques 17, 372–375PubMedGoogle Scholar
  11. 11.
    Uhlenbeck, O C (1987) A small catalytic oligoribonucleotide. Nature 328, 596–600PubMedCrossRefGoogle Scholar
  12. 12.
    Fedor, M J and Uhlenbeck, O C. (1990) Substrate sequence effect on “hammerhead” RNA catalytic efficiency. Proc Natl Acad Sci USA 87, 1668–1672PubMedCrossRefGoogle Scholar
  13. 13.
    Milligan, J F, Groebe, D. R, Witherell, G W, and Uhlenbeck, O. C (1987) Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates Nucleic Acids Res 15, 8783–8798PubMedCrossRefGoogle Scholar
  14. 14.
    Scanlon, K J, Jiao, L., Funato, T, Wang, W., Tone, T, Rossi, J. J., and KashaniSabet, M (1991) Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl Acad Sci USA 88, 10,591–10,595PubMedCrossRefGoogle Scholar
  15. 15.
    Sane, D C and Deidra, J C (1995) PCR-based production of a ribozyme to plasminogen activator inhibitor-1. Bio Techniques 18, 208–210Google Scholar
  16. 16.
    Haseloff, J and Gerlach, W. L. (1988) Simple RNA enzymes with new and highly specific endoribonuclease activities Nature 334, 585–591PubMedCrossRefGoogle Scholar
  17. 17.
    Roldan, A. L, Cubellis, M V., Masucci, M. T., Behrendt, N., Lund, L R, Dano, K, Appella, E., and Blasi, F. (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface plasmin dependent proteolysis. EMBO J 9, 467–474PubMedGoogle Scholar
  18. 18.
    Ausubel, F M, Brent, R, Kingston, R E, Moore, D D., Seidmar, J G, Smith, J A., Struhl, K, eds (1992) Current Protocols in Molecular Biology. New York Wiley Interscience.Google Scholar
  19. 19.
    Czerny, T. (1996) High primer concentration improves PCR amplification from random pools. Nucleic Acids Res 24, 985–986PubMedCrossRefGoogle Scholar
  20. 20.
    Liang, P and Pardee, A B (1992) Differential display of eukariotic messenger RNA by means of the polymerase chain reaction. Science 257, 967–971.PubMedCrossRefGoogle Scholar
  21. 21.
    Lyamichev, V., Brow, M.A.D, and Dahlberg, J E (1993) Structure-specific endonucleolytic cleavage of nucleic acids by eubacterial DNA polymerases. Science 260, 778–783PubMedCrossRefGoogle Scholar
  22. 22.
    Karikó, K., Megyeri, K, Xiao, Q, and Barnathan, E B (1994) Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett 352, 41–44.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1998

Authors and Affiliations

  • Katalin Karikó
    • 1
  • Elliot S. Barnathan
    • 2
  1. 1.Neurosurgery and Cardiovascular DivisionUniversity of Pennsylvania School of MedicinePhiladelphia
  2. 2.Cardiovascular DivisionUniversity of PennsylvaniaPhiladelphia

Personalised recommendations